CN1655819A - 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物 - Google Patents

包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物 Download PDF

Info

Publication number
CN1655819A
CN1655819A CNA03811237XA CN03811237A CN1655819A CN 1655819 A CN1655819 A CN 1655819A CN A03811237X A CNA03811237X A CN A03811237XA CN 03811237 A CN03811237 A CN 03811237A CN 1655819 A CN1655819 A CN 1655819A
Authority
CN
China
Prior art keywords
diabetic
renal
disease
hypertension
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA03811237XA
Other languages
English (en)
Chinese (zh)
Inventor
D·L·费尔德曼
R·L·韦布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1655819(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1655819A publication Critical patent/CN1655819A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CNA03811237XA 2002-05-17 2003-05-16 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物 Pending CN1655819A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38154602P 2002-05-17 2002-05-17
US60/381,546 2002-05-17

Publications (1)

Publication Number Publication Date
CN1655819A true CN1655819A (zh) 2005-08-17

Family

ID=29550141

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA03811237XA Pending CN1655819A (zh) 2002-05-17 2003-05-16 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物

Country Status (24)

Country Link
US (3) US20050182042A1 (cg-RX-API-DMAC7.html)
EP (2) EP1507558B8 (cg-RX-API-DMAC7.html)
JP (2) JP5288678B2 (cg-RX-API-DMAC7.html)
KR (3) KR20130109244A (cg-RX-API-DMAC7.html)
CN (1) CN1655819A (cg-RX-API-DMAC7.html)
AT (1) ATE520417T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003240669B2 (cg-RX-API-DMAC7.html)
BR (1) BR0310084A (cg-RX-API-DMAC7.html)
CA (1) CA2485081C (cg-RX-API-DMAC7.html)
CY (2) CY1112013T1 (cg-RX-API-DMAC7.html)
DK (1) DK1507558T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP045428A (cg-RX-API-DMAC7.html)
ES (1) ES2369216T3 (cg-RX-API-DMAC7.html)
IL (1) IL164837A (cg-RX-API-DMAC7.html)
LU (1) LU92000I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA04011383A (cg-RX-API-DMAC7.html)
NO (1) NO334382B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ536555A (cg-RX-API-DMAC7.html)
PL (1) PL219032B1 (cg-RX-API-DMAC7.html)
PT (1) PT1507558E (cg-RX-API-DMAC7.html)
RU (1) RU2316318C2 (cg-RX-API-DMAC7.html)
SI (1) SI1507558T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003097098A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200408442B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN102552277A (zh) * 2011-12-02 2012-07-11 邬林祥 氨氯地平、阿利可仑和氢氯噻嗪复方降压药物
CN115243774A (zh) * 2019-04-08 2022-10-25 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2003097098A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
CA2525970C (en) 2003-05-15 2011-03-22 Roskamp Research, Llc Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
AR047880A1 (es) * 2004-02-17 2006-03-01 Novartis Ag COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
AU2005224014B9 (en) * 2004-03-17 2009-08-27 Novartis Ag Use of organic compounds
NZ551666A (en) * 2004-05-31 2010-07-30 Almirall Lab Combinations comprising antimuscarinic agents and beta-adrenergic agonists
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
JP2008538549A (ja) * 2005-03-22 2008-10-30 ノバルティス アクチエンゲゼルシャフト 高血圧剤としてのアリスキレンの有効性に関するバイオマーカー
AU2006311723A1 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
AR063560A1 (es) * 2006-11-07 2009-02-04 Novartis Ag Compuestos organicos
AR063597A1 (es) * 2006-11-09 2009-02-04 Novartis Ag Nueva sal
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
JP2010518147A (ja) * 2007-02-16 2010-05-27 ノバルティス アーゲー 有機化合物の使用
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
RU2363472C2 (ru) * 2007-05-22 2009-08-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ профилактики и лечения кардиоваскулярных осложнений у больных с хронической болезнью почек, находящихся на гемодиализе, имеющих анурию
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
JP5411145B2 (ja) 2007-10-05 2014-02-12 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド （−）−ニルバジピンエナンチオマーによってアミロイド沈着、アミロイド神経毒性、およびミクログリオーシスを減少させる方法
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
RU2373932C1 (ru) * 2008-05-20 2009-11-27 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии
RU2372079C1 (ru) * 2008-05-20 2009-11-10 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии, дислипидемии и нарушении толерантности к глюкозе
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
JP5980508B2 (ja) * 2009-03-11 2016-08-31 プロメディオール， インコーポレイテッド 自己免疫障害に対する処置方法
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) * 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
GB201317373D0 (en) 2013-10-01 2013-11-13 Univ Dundee Treatment and prevention of cancer
KR102414285B1 (ko) * 2020-06-02 2022-06-28 이화여자대학교 산학협력단 플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350771A (en) * 1989-03-22 1994-09-27 Peter K. T. Pang Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers
JP3398379B2 (ja) * 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンｉｉ受容体遮断組成物
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
US5178877A (en) * 1991-01-04 1993-01-12 Abbott Laboratories Encapsulated renin inhibitor composition
US5114925A (en) * 1991-01-22 1992-05-19 Merck & Co., Inc. Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
JP4194095B2 (ja) * 2001-09-11 2008-12-10 旭化成ファーマ株式会社 脳血管障害、心疾患の予防・治療用医薬組成物
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
WO2003097098A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN102552277A (zh) * 2011-12-02 2012-07-11 邬林祥 氨氯地平、阿利可仑和氢氯噻嗪复方降压药物
CN115243774A (zh) * 2019-04-08 2022-10-25 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
CN115243774B (zh) * 2019-04-08 2024-05-24 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物

Also Published As

Publication number Publication date
ES2369216T3 (es) 2011-11-28
JP2005526850A (ja) 2005-09-08
KR20130109244A (ko) 2013-10-07
US8183295B2 (en) 2012-05-22
PL219032B1 (pl) 2015-03-31
IL164837A (en) 2013-12-31
US20120071470A1 (en) 2012-03-22
EP1507558A1 (en) 2005-02-23
AU2003240669A1 (en) 2003-12-02
BR0310084A (pt) 2005-02-15
PT1507558E (pt) 2011-11-23
US20050182042A1 (en) 2005-08-18
IL164837A0 (en) 2005-12-18
CY2012011I2 (el) 2015-11-04
CA2485081A1 (en) 2003-11-27
PL372203A1 (en) 2005-07-11
AU2003240669B2 (en) 2007-03-08
ZA200408442B (en) 2006-02-22
ATE520417T1 (de) 2011-09-15
US20080300238A1 (en) 2008-12-04
CY1112013T1 (el) 2015-11-04
JP5288678B2 (ja) 2013-09-11
ECSP045428A (es) 2005-01-03
DK1507558T3 (da) 2011-12-05
NO20045459L (no) 2004-12-15
MXPA04011383A (es) 2005-02-14
RU2004137104A (ru) 2005-09-10
SI1507558T1 (sl) 2011-12-30
KR20100137026A (ko) 2010-12-29
CA2485081C (en) 2013-01-08
KR20050008717A (ko) 2005-01-21
EP2316488A1 (en) 2011-05-04
JP2010280708A (ja) 2010-12-16
NZ536555A (en) 2007-03-30
NO334382B1 (no) 2014-02-24
CY2012011I1 (el) 2015-11-04
EP1507558B8 (en) 2012-02-15
HK1074774A1 (en) 2005-11-25
RU2316318C2 (ru) 2008-02-10
EP1507558B1 (en) 2011-08-17
LU92000I2 (fr) 2012-07-16
WO2003097098A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
CN1655819A (zh) 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物
EP1467728B1 (en) Pharmaceutical compositions comprising valsartan and nep inhibitors
US8101659B2 (en) Methods of treatment and pharmaceutical composition
CA2678722C (en) Antihypertensive combination of valsartan and a calcium channel blocker
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
WO2007045663A2 (en) Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
HK1156212A (en) Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
HK1074774B (en) Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD.